Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction
Sponsor: Hospital Clinic of Barcelona
Summary
The DAPA-STEMI trial investigates whether dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), reduces heart muscle scarring (fibrosis) and improves heart function after a ST-segment elevation myocardial infarction (STEMI). The trial will use cardiac MRI to measure changes in heart structure and function over six months. Patients aged 30-85 who have had a recent STEMI will receive either dapagliflozin or a placebo. The study aims to provide mechanistic insights into heart failure prevention after heart attacks.
Key Details
Gender
All
Age Range
30 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
54
Start Date
2021-05-30
Completion Date
2025-03-31
Last Updated
2025-02-19
Healthy Volunteers
No
Conditions
Interventions
Dapagliflozin
Dapagliflozin 10 mg qd
Placebo
Matched placebo qd
Locations (2)
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, Spain
Hospital Clinic of Barcelona
Barcelona, Catalonia, Spain